Actually, the only pharmacological inhibitors of NFκB approved for clinical use are proteasome inhibitors for treatment of multiple myeloma or adult T-cell leukaemia, for whose pathogenesis it has been clearly demonstrated the key role of NFκB. This evidence concerns the gene NFKB1 and AL amyloidosis.